Presentations on two novel Zealand preclinical peptide

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Presentations on two novel Zealand preclinical peptide therapeutics as possible approaches for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions
  • Zealand presents new data on two of its novel preclinical peptide therapeutics; dual acting GLP-1-GIP and GLP-1-gastrin receptor agonists, both representing potential new strategies for the treatment of Type 2 diabetes and obesity

Copenhagen, 6 June 2015 – Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) today informs that new data will be presented on two novel peptide therapeutics from the company’s preclinical pipeline at the upcoming 75th Scientific Sessions of the American Diabetes Association (ADA), taking place 5 – 9 June 2015 in Boston.

Keld Fosgerau, acting SVP for Research for Zealand, commented: "We are pleased to have been given the opportunity to present two of our novel dual-acting peptide therapeutics from our preclinical pipeline at ADA. All three presentations are valuable examples of Zealand’s capabilities in the design and development of medicines representing new approaches to disease management.”

Scientists from Zealand will present data on two of the company’s novel and promising preclinical peptide therapeutics, ZP-DI-70 and ZP3022, representing co-activation of GLP-1 and GIP receptors and of GLP-1 and gastrin, respectively. The company will also outline new findings which demonstrate the suitability of the co-activation of GLP-1 and GIP receptors:

“Pharmacokinetics and pharmacodynamics of GLP-1-GIP receptor dual agonist peptides: from once-daily to once-weekly” – Abstract # 2086-P – POSTER PRESENTATION

When:           Presented on Saturday, June 6, 2015 11:30 AM Eastern

Presenter:     Maria A. Deryabina, Scientist, Zealand, Denmark

Location:       Board 2086

Introduction and conclusion

This presentation will outline new findings underscoring the suitability of the co-activation of GLP-1 and GIP receptors as a promising new strategy for the treatment of Type 2 diabetes and obesity. The presented pharmacokinetic and pharmacodynamic results demonstrate the possibility of prolonging the activity of GLP1-GIP dual agonists, which builds on existing evidence from animal studies which suggests that the anti-obesity efficacy of GLP-1 can be enhanced by co-administration with the incretin hormone GIP.

“An optimized novel GLP-1-GIP receptor dual agonist with potent effects on body weight and glucose control in mice has the potential for once-weekly administration in humans.” – Abstract # 2061-P – POSTER PRESENTATION

When:           Presented on Saturday, June 6, 2015 11:30 AM Eastern

Presenter:     Carsten B. Knudsen, Scientist, Zealand, Denmark

Location:       Board 2061

Introduction and conclusion

The data to be presented here suggest ZP-DI-70, a novel, potent and selective GLP-1-GIP receptor dual agonist, as a promising candidate for the treatment of T2D with superior body weight lowering effect compared to existing therapies. The in vivo profile of the compound further suggests that ZP-DI-70 could be used as a convenient once-weekly treatment.

ZP-DI-70 has demonstrated promising effects on glucose control and body weight reduction in preclinical mouse models. Furthermore, pharmacokinetic evaluation in mice and monkeys indicate the potential for convenient once-weekly dosing in humans for improved treatment compliance.

“Effect of GLP-1-Gastrin Dual Agonist ZP3022 on Pancreas Gene Expression in ZDF Rats”, Abstract # 2085-P – POSTER PRESENTATION

When:           Presented on Saturday, June 6, 2015 11:30 AM Eastern

Presenter:     Jolanta Skarbaliene, Scientist, Zealand, Denmark

Location:       Board 2085

Introduction and conclusion

Zealand’s GLP-1-gastrin dual agonist ZP3022 has been shown to increase β cell mass and improve glycemic control in db/db mice and Zucker Diabetic Fatty (ZDF) rats. Here we investigated alteration in pancreas gene expression following treatment with ZP3022 in ZDF rats.

We conclude that ZP3022 produces a different gene expression response compared to exendin-4 given alone or in combination with gastrin17 and may have therapeutic potential in the prevention/delay of β cell dysfunction.

●●●●●

For further information, please contact:

Britt Meelby Jensen, President and Chief Executive Officer

Tel: +45 51 67 61 28, email: bmj@zealandpharma.com

Hanne Leth Hillman, Senior Vice President, Head of Investor Relations & Corporate Communications

Tel: +45 50 60 36 89, email: hlh@zealandpharma.com

About Zealand Pharma

Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a proprietary pipeline of novel medicines alongside a partnered product and development portfolio.

Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and is in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory filing for Lyxumia® is planned for Q3 2015 and filing for LixiLan is planned for Q4 2015 in the US and Q1 2016 in Europe.

Zealand’s proprietary pipeline includes danegaptide (prevention of Ischemic Reperfusion Injury) and two stable glucagon products, ZP4207 (one for treatment of severe hypoglycemia and the other for mild to moderate hypoglycemia) as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.

For further information: www.zealandpharma.com     Follow us on Twitter @ZealandPharma

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 47

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 56

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 142

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Webull Faces FINRA Fine and Legal Battle Ahead

Updated Category News Views 187

Webull's Compliance Headache Webull’s been knocked around again. This time, the Financial Industry Regulatory Authority (FINRA) slapped it with a hefty $4.2 million fine. Talk about a hit to the wallet! It all boils down to them failing to roll out some basic anti-money laundering (AML) and other crucial compliance programs. This is no small oversight, and it's got...

Continue Reading
Clinch Scores Big with Two Prestigious Industry Honors

Updated Category News Views 101

Clinch's Dual Triumph in Advertising Innovation No one throws a ticker symbol over their cereal for recognizing brilliance, but when an outfit like Clinch gets double applause at the big dance, even we old-timers have to tip our hats. On November 16, 2026, the advertising world saw some fireworks. Clinch took home not one but two hefty awards—the kind that say you've...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Luxury Villa Cashback Offers Entice Travelers in November

Updated Category News Views 134

A November Bonanza for Villa Bookings Who doesn't love having a few extra bucks in their pocket, especially when they come with the allure of luxury travel? Villas of Distinction is rolling out what they call a 'November Cashback Offer,' and for those with the wallet—and wanderlust—to match, it could be a tempting proposition. Hanging the bait of up to $2,000 cashback...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 150

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Tenax Therapeutics Facing Class Action: DEC 28 Deadline

Updated Category News Views 92

Legal Storm Over Tenax Therapeutics Just what the doctor didn't order—legal headaches for Tenax Therapeutics, Inc. (NASDAQ:TENX). Yup, folks, buckle up because we're diving into another class action mudslinging match that’s setting the markets wagging. Berger Montague's law trebuchet is aimed squarely at Tenax and every investor should know the target’s outline....

Continue Reading

Top 5 Most Recently Viewed Articles

Macquarie's Optimistic Outlook for Chinese Internet Stocks

Updated Category News Views 155

Macquarie's Recent Upgrades in the Chinese Internet Sector Macquarie has taken a positive stance on various Chinese internet stocks, highlighting the stronger fundamentals and increased earnings visibility that have emerged in the sector. Analysts believe that ongoing support from the government will further bolster these companies, leading to enhanced growth...

Continue Reading
Highmark Health's Impressive Financial Growth and Future Outlook

Updated Category News Views 238

Highmark Health Reports Impressive Financial Results In a remarkable update, Highmark Health shared its consolidated financial outcomes for the first half of 2025, revealing a revenue of $16.5 billion, alongside a net income of $329 million. This performance is indicative of the organization's robust positioning within the healthcare sector, despite facing ongoing...

Continue Reading
Roblon Reports Steady Q1 Performance Amid Market Challenges

Updated Category News Views 136

Roblon A/S Delivers Steady Financial Results in Q1 2024/25 Roblon’s revenue and earnings for the first quarter of 2024/25 meet expectations The Board of Directors at Roblon A/S has reviewed and approved the interim report reflecting the company’s performance over the initial three months of the financial year 2024/25. This period showcased resilient revenue figures,...

Continue Reading
Weis Markets Achieves Notable Growth in Third Quarter 2025

Updated Category News Views 188

Weis Markets Shows Strong Third Quarter Performance Weis Markets, Inc. (NYSE: WMK) has reported impressive financial results for its third quarter. The company saw an increase of 2.5% in comparable store sales excluding fuel, showcasing its resilience in a fluctuating economic landscape. Overview of Third Quarter Results In the 13-week period ending September 27, 2025,...

Continue Reading
Innovative Renal Care Faces Investigation Over Major Data Breach

Updated Category News Views 156

Innovative Renal Care Under Investigation for Data Breach In recent developments, Innovative Renal Care has come under scrutiny due to a significant data breach that has alarmed both the company and its patients. The investigation, spearheaded by Federman & Sherwood, seeks to uncover the full extent of the incident and understand its implications. Details of the Data...

Continue Reading